Century Therapeutics (IPSC) Operating Leases (2020 - 2026)

Century Therapeutics (IPSC) has reported Operating Leases for 7 consecutive years, with $43.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 8.06% year-over-year to $43.9 million; the TTM figure through Mar 2026 stood at $43.9 million (down 8.06% YoY), while the FY2025 annual figure was $40.2 million, down 17.81% from the prior year.
• Operating Leases climbed to $43.9 million in Q1 2026 per IPSC's latest filing, from $40.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $52.7 million in Q2 2024 and bottomed at $14.4 million in Q1 2022.
• Historically, Operating Leases has averaged $41.8 million across 5 years, with a median of $43.9 million in 2026.
• Annual changes were most pronounced in 2023 — Operating Leases soared 185.29% — and 2025, when it decreased 18.99%.
• Century Therapeutics' Operating Leases stood at $38.7 million in 2022, then advanced by 20.57% to $46.7 million in 2023, then advanced by 4.93% to $49.0 million in 2024, then slipped by 17.81% to $40.2 million in 2025, then grew by 9.2% to $43.9 million in 2026.
• Business Quant data shows IPSC's Operating Leases at $43.9 million in Q1 2026, $40.2 million in Q4 2025, and $41.2 million in Q3 2025.